Serpinf2-binding molecules and method of use thereof
AssigneeTranslational Sciences Inc.
InventorGuy L. Reed
Life of this patent
Estimating the term…
Abstract
Compositions and methods of using SerpinF2-binding molecules for preventing and/or reducing organ damage, functional disability or mortality in a patient at risk due to the activity of SerpinF2 and/or plasminogen activators on tissue injury. Also provided are compositions and methods of using SerpinF2-binding molecules for inhibiting hemorrhage, edema, and apoptosis. Methods for the preparation of medicaments for such methods of treatment and prevention are provided.
Claims17
A method of inhibiting disability or death from endogenous or pharmacologic tissue plasminogen activator (TPA) toxicity due to ischemia from stroke in a patient in need thereof, the method comprising:
- determining that the patient has or is at risk for TPA toxicity due to prolonged ischemia of at least three hours;
- and
- administering, in response to the determining the patient has or is at risk for TPA toxicity due to prolonged ischemia of at least three hours, to the patient an effective amount of a composition comprising an anti-SerpinF2 antibody or fragment thereof that reduces SerpinF2 activity or concentration, wherein the composition does not include TPA, thereby inhibiting disability or death from TPA toxicity due to ischemia from stroke.
A method of inhibiting disability or death from endogenous or pharmacologic tissue plasminogen activator (TPA) mediated neurologic hemorrhage or edema in a patient in need thereof, the method comprising:
- determining that the patient has or is at risk for TPA toxicity due to prolonged ischemia of at least three hours;
- and
- administering, in response to the determining the patient has or is at risk for TPA toxicity due to prolonged ischemia of at least three hours, to the patient an effective amount of a composition comprising an anti-SerpinF2 antibody or fragment thereof that reduces SerpinF2 activity or concentration, wherein the composition does not include TPA, thereby inhibiting disability or death from TPA mediated neurologic hemorrhage or edema.
A method of treating stroke in a patient affected by TPA toxicity, the method comprising:
- determining that the patient has or is at risk for TPA toxicity due to prolonged ischemia of at least three hours;
- and
- administering, in response to the determining the patient has or is at risk for TPA toxicity due to prolonged ischemia of at least three hours, to the patient an effective amount of a composition comprising an anti-SerpinF2 antibody or fragment thereof that reduces SerpinF2 activity or concentration, wherein the composition does not include TPA, thereby treating stroke in the patient affected by TPA toxicity.
Dependencies are inferred from the claim text.